KA/EN
Register
Medicines reference
Search
Search
Product

Telmista

Favourites

Telmisartan · Krka

2 forms: tablet. In force in Georgia: 2 of 2 (human register).

Forms and doses2 of 2 in force in Georgia

Form Dose Frequency Georgia
40 mg, Tablet No label dose in the reference yet - Georgia Yes, human
In force until 15 Apr 2030
Human (Ministry of Health, RAMA)
In the register: ტელმისტა 40მგ აბი #28, #84
№ რ-043128, რ-043129
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Telmista 40 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists
6.4/10
Situational / acceptable
vetman assessment

Telmista

40 mg, tablet, human medicine
Assessed clinical scopeDog · Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 6.4/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-043128, რ-043129 · Verified on 16 Oct 2026 Off-label use

Telmisartan has credible canine antiproteinuric evidence, but this 40 mg human tablet is off-label and its half-tablet step limits accurate dosing. Use only when the calculated dose is physically deliverable or prescribe a verified compounded liquid, with early renal, potassium, pressure and UPC review.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A double-masked randomized trial in dogs with persistent renal proteinuria found a larger UPC reduction with telmisartan than enalapril through day 90; two additional clinical cohorts support antiproteinuric and blood-pressure effects. The trials used a liquid preparation, so equal tablet dose delivery must not be assumed.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality4.5/10

The smallest recorded half-tablet is 20 mg, a coarse 20 kg dose step at 1 mg/kg. It can fit selected large dogs but is poor for smaller patients or response-guided titration without verified compounding.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Dog telmisartan RCT2020
  6. Dog telmisartan retrospective2021
  7. Dog telmisartan CKD 20202020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available
5.8/10
Weak evidence support
vetman assessment

Telmista

40 mg, tablet, human medicine
Assessed clinical scopeCat · Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 5.8/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-043128, რ-043129 · Verified on 16 Oct 2026 Off-label use

Telmisartan is evidence-based in cats, but this 40 mg human tablet is a poor and potentially hazardous match to the small feline dose. Prefer the authorised 4 mg/ml veterinary solution or a validated patient-specific liquid and monitor renal function, potassium, pressure and UPC.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A 224-cat randomized blinded trial and current CKD consensus support telmisartan for persistent feline renal proteinuria, while a separate controlled trial supports antihypertensive efficacy. These data establish the active ingredient, not accurate dosing from these very high-strength human tablets.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality0.5/10

A half-tablet is 20 mg, far above a typical cat dose. This presentation is not directly doseable for cats and would require validated pharmacy compounding; the authorised feline liquid is markedly preferable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Cat telmisartan RCT2015
  6. iCatCare feline CKD 20262026
  7. FDA feline telmisartan FOI2018
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Telmisartan40 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Krka · Slovenia
Registration
Georgia Yes, human
In force until 15 Apr 2030
Human (Ministry of Health, RAMA)
In the register: ტელმისტა 40მგ აბი #28, #84
№ რ-043128, რ-043129
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
80 mg, Tablet No label dose in the reference yet - Georgia Yes, human
In force until 15 Apr 2030
Human (Ministry of Health, RAMA)
In the register: ტელმისტა 80მგ აბი #28, #84
№ რ-043130, რ-043131
Verified on: 16 Oct 2026
Details: pack, label wording, sources, registration

Telmista 80 mg, Tablet

tablet, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists
6.2/10
Situational / acceptable
vetman assessment

Telmista

80 mg, tablet, human medicine
Assessed clinical scopeDog · Off-label oral telmisartan for persistent renal proteinuria in dogs, with blood-pressure benefit considered when hypertension coexists · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 6.2/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, human · № რ-043130, რ-043131 · Verified on 16 Oct 2026 Off-label use

Telmisartan has credible canine antiproteinuric evidence, but this 80 mg human tablet is off-label and its half-tablet step limits accurate dosing. Use only when the calculated dose is physically deliverable or prescribe a verified compounded liquid, with early renal, potassium, pressure and UPC review.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A double-masked randomized trial in dogs with persistent renal proteinuria found a larger UPC reduction with telmisartan than enalapril through day 90; two additional clinical cohorts support antiproteinuric and blood-pressure effects. The trials used a liquid preparation, so equal tablet dose delivery must not be assumed.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality3.0/10

The smallest recorded half-tablet is 40 mg, a very coarse 40 kg dose step at 1 mg/kg. Direct use is limited to selected very large dogs; most patients require a lower strength or verified compounded liquid.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Dog telmisartan RCT2020
  6. Dog telmisartan retrospective2021
  7. Dog telmisartan CKD 20202020
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available
5.7/10
Weak evidence support
vetman assessment

Telmista

80 mg, tablet, human medicine
Assessed clinical scopeCat · Off-label oral telmisartan for persistent renal proteinuria and selected blood-pressure control in cats when an accurately prepared patient-specific dose is available · By mouth
Care settingVeterinary-prescribed home treatment after persistent renal proteinuria and hydration status are confirmed, using an accurately deliverable dose with UPC, pressure, creatinine and potassium follow-up
vetman score 5.7/10 Weak evidence support
Evidence confidence: Medium Georgia: Yes, human · № რ-043130, რ-043131 · Verified on 16 Oct 2026 Off-label use

Telmisartan is evidence-based in cats, but this 80 mg human tablet is a poor and potentially hazardous match to the small feline dose. Prefer the authorised 4 mg/ml veterinary solution or a validated patient-specific liquid and monitor renal function, potassium, pressure and UPC.

Regulatory and scientific credibility6.0/10

The exact human tablet is currently registered in Georgia with a sourced strength and manufacturer, but no current exact trade-name match exists in the checked EU/EEA, UK or US registers and no tablet is authorised for veterinary use. Veterinary telmisartan is transparently authorised in cats, but those liquid labels do not validate this tablet presentation.

Clinical efficacy8.0/10

A 224-cat randomized blinded trial and current CKD consensus support telmisartan for persistent feline renal proteinuria, while a separate controlled trial supports antihypertensive efficacy. These data establish the active ingredient, not accurate dosing from these very high-strength human tablets.

Safety and tolerability6.5/10

Veterinary studies and labels define the main risks, but these exact human tablets have no species-specific safety dossier. Hypotension, dehydration-associated renal decline, azotaemia and hyperkalaemia require baseline selection and early reassessment; combining RAAS blockers can materially increase renal risk.

Clinical practicality0.0/10

A half-tablet is 40 mg, far above a typical cat dose. This presentation is not directly doseable for cats and would require validated pharmacy compounding; the authorised feline liquid is markedly preferable.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Do not start during dehydration, hypovolaemia, clinically important hypotension or acute kidney injury; stabilise the patient and establish persistent renal proteinuria first.
  • Do not routinely combine telmisartan with another ARB or an ACE inhibitor; dual RAAS blockade can cause hypotension, hyperkalaemia and clinically important renal decline.
  • Measure UPC from appropriately collected urine and assess blood pressure, creatinine/SDMA, potassium and hydration before treatment; repeat soon after starting or increasing the dose.
  • Review diuretics, NSAIDs and other medicines that lower pressure or renal perfusion; illness with poor intake, vomiting or diarrhoea can make temporary interruption necessary.
  • Reassess if creatinine rises materially, potassium increases, appetite or weight falls, weakness or syncope develops, or systolic pressure becomes too low.
  • Treat the underlying cause and use a renal diet where indicated; a lower UPC is a response marker, not proof that chronic kidney disease has stopped progressing.
  • The feline 1 mg/kg proteinuria regimen and the higher hypertension regimen are not interchangeable. Confirm the exact concentration and indication before calculating millilitres.
  • Reproductive safety is not established for veterinary use; the exact 4 mg/ml feline label contraindicates use during pregnancy and lactation.
Assessment sources
  1. Telmisartan market audit2026
  2. Telmitraxx 4 mg/ml SPC2026
  3. Semintra EPAR2024
  4. IRIS 20262026
  5. Cat telmisartan RCT2015
  6. iCatCare feline CKD 20262026
  7. FDA feline telmisartan FOI2018
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Telmisartan80 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
Krka · Slovenia
Registration
Georgia Yes, human
In force until 15 Apr 2030
Human (Ministry of Health, RAMA)
In the register: ტელმისტა 80მგ აბი #28, #84
№ რ-043130, რ-043131
Verified on: 16 Oct 2026
 EU No
Verified on: 16 Oct 2026
 UK No
Verified on: 16 Oct 2026
 US No
Verified on: 16 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Active substance doses, with sources

Each dose comes with its source. Check the label of the product you use.

Active substance Telmisartan
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
1 mg/kg Cat Proteinuria in Chronic Kidney Disease By mouth once daily
VMD SPC 2023
Official product label (SPC), VMD, UK
Approved by the UK Veterinary Medicines Directorate (VMD) as part of the product's authorisation. It applies to that product as authorised there.
Telmitraxx 4 mg/ml oral solution for cats - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2023
2 mg/kg Cat Systemic Hypertension By mouth once daily
IRIS 2026
Guideline or consensus statement
Recommendations agreed by a panel of veterinary specialists after reviewing the evidence. They guide practice and do not authorise a product.
IRIS Treatment Recommendations for Chronic Kidney Disease in Cats and in Dogs (2026)
IRIS, 2026

Known Contraindications

  • Critical
    Do not use during pregnancy or lactation.
    Sources: VMD SPC · VMD
  • Critical
    Do not use during pregnancy or lactation.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in cases of hypersensitivity to the active substance or to any of the excipients.
    Sources: VMD SPC · VMD
  • Critical
    Do not give a RAAS inhibitor to a cat that is clinically dehydrated or shows signs of hypovolaemia. Restore hydration first.
    Sources: IRIS
  • Warning
    In cats with severe kidney disease, drugs acting on the RAAS can lower the glomerular filtration rate and worsen kidney function. The safety and efficacy of telmisartan in these cats have not been studied.
    Sources: VMD SPC · VMD · IRIS
  • Warning (Cat)
    The safety and efficacy of telmisartan has not been tested in cats under the age of 6 months.
    Sources: VMD SPC · VMD
  • Caution
    Elevated liver enzymes... Values normalised within a few days following cessation of therapy.
    Sources: VMD SPC · VMD

Known Drug Interactions

  • Major warning Benazepril + Telmisartan
    Available data in cats with CKD show no known interaction between telmisartan and other drugs acting on the RAAS (ARBs, ACE inhibitors), but combining drugs that act on the RAAS can change kidney function.
    Recommendation: Use an ACE inhibitor and an angiotensin-receptor blocker together only after an individual benefit-risk assessment. Monitor creatinine, potassium, blood pressure, and hydration closely so deterioration in renal function is detected promptly.
    Sources: VMD SPC · VMD · IRIS
  • Minor warning Telmisartan + Amlodipine
    During concomitant therapy with amlodipine at the recommended dose, no clinical evidence of hypotension was observed.
    Recommendation: Combine amlodipine and telmisartan only when either drug alone does not control blood pressure adequately. Measure blood pressure before treatment, correct dehydration, and recheck regularly after stabilisation.
    Sources: VMD SPC · VMD · IRIS

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (26 more) Hide additional products

Same therapeutic group 26

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 16 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗